AT-rich interactive domain containing protein 1A (ARID1A), a subunit of the chromatin remodeling complex, has been established as a tumor suppressor gene. Its inactivation has been reported to drive mutation in carcinogenesis of different tumor types, most notably ovarian clear cell carcinoma.
proliferation and to activate cyclin-dependent kinase inhibitor 1A (CDKN1A) transcription, supporting the idea that ARID1A is a cancer-driving gene. 5, 8 How do we use this information in our clinical practice? Currently, the presence of BRAF V600E mutation is helpful in distinguishing sporadic from Lynch syndrome-associated MMR-deficient CRC cases. However, only two-thirds of the sporadic MLH1 promoter methylated cases show BRAF V600E mutation. 4 ARID1A immunohistochemistry could potentially be used as an additional tool to exclude Lynch syndrome-associated CRC. Further studies looking at ARID1A expression in Lynch syndrome patients and the validity of this method in addition to reflex BRAF mutation testing in MLH1-deficient tumors are necessary to determine the utility of this testing. The prognostic information on different tumor types from recent published studies has been based on a limited number of cases with loss of ARID1A expression. 3, 5, 7 Additional data are required to support the reported prognostic significance of ARID1A expression loss in CRC and SIC patients. Finally, a recent study reported Enhancer of Zeste Homolog 2/EZH2 as a potential therapeutic target in ARID1A-mutated cancers. 9 ARID1A mutational status will become important information for CRC and SIC patients when targeted therapies become available in the future.
